CA Patent

CA2363053C — Clopidogrel bisulfate tablet formulation

Assigned to Individual · Expires 2011-01-25 · 15y expired

What this patent protects

Pharmaceutical tablets comprising clopidogrel bisulfate and a lubricant selected from zinc stearate, stearic acid, and sodium stearyl fumarate.

USPTO Abstract

Pharmaceutical tablets comprising clopidogrel bisulfate and a lubricant selected from zinc stearate, stearic acid, and sodium stearyl fumarate.

Drugs covered by this patent

Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim

Patent Metadata

Patent number: CA2363053C
Jurisdiction: CA
Classification: —
Expires: 2011-01-25
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.